tBID activates BAX, an effector of apoptosis (Westphal et al., 2014), and the cancer chemotherapy drug gemcitabine promotes BAX-dependent apoptosis of a glioma cell line via lysosomal ceramide accumulation and cathepsin D activation (Dumitru et al., 2009). Here, BID is linked to glioma.